Sushil Patel
Fortuna: 10 M $ al 31/05/2026
Fortuna: 10 M $ al 31/05/2026
Sushil Patel is Chief Executive Officer & Director at Replimune Group, Inc. since 2024 and an Independent Director at Revolution Medicines, Inc. since 2022.
Formerly, Dr. Patel was Vice President-Franchise & Head-Oncology at Genentech, Inc. from 2018 to 2021.
Education includes an undergraduate degree from the University of Warwick in 1992, a graduate degree from Imperial College London in 1993, and a doctorate from the University of London in 1999.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
REPLIMUNE GROUP, INC. 0,96 % | 18/05/2026 | 747.492 ( 0,96 % ) | 6 M $ | 31/05/2026 |
| 29/06/2026 | 21.656 ( 0,01 % ) | 3 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| REPLIMUNE GROUP, INC. | Director Ejecutivo | 01/04/2024 |
| REVOLUTION MEDICINES, INC. | Director/Miembro de la Junta | 16/06/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01/05/2021 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 6 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Imperial College London
Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Warwick
University of Warwick Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Revolution Medicines, Inc.
Revolution Medicines, Inc. Pharmaceuticals: OtherHealth Technology Develops new therapies derived from natural products | Health Technology |
Replimune Group, Inc.
Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.